Small Lymphocytic Lymphoma: Analysis of Two Cohorts Including Patients in Clinical Trials of the German Chronic Lymphocytic Leukemia Study Group (GCLLSG) or in "Real-Life" Outside of Clinical Trials

被引：3

作者：

Sachanas, Sotirios ^{[1
]}

Pangalis, Gerassimos A. ^{[1
]}

Fink, Anna-Maria ^{[2
,3
]}

Bahlo, Jasmin ^{[2
,3
]}

Fischer, Kirsten ^{[2
,3
]}

Levidou, Georgia ^{[3
,4
,5
]}

Kyrtsonis, Marie-Christine ^{[6
]}

Bartzi, Vassiliki ^{[7
]}

Vassilakopoulos, Theodoros P. ^{[8
]}

Kalpadakis, Christina ^{[9
]}

Koulieris, Efstathios ^{[1
]}

Moschogiannis, Maria ^{[1
]}

Yiakoumis, Xanthi ^{[1
]}

Tsirkinidis, Pantelis ^{[1
]}

Angelopoulou, Maria K. ^{[8
]}

Eichhorst, Barbara ^{[2
,3
]}

Hallek, Michael ^{[2
,3
]}

机构：

[1] Athens Med Ctr, Psychikon Branch, Dept Haematol, 1 Andersen Str, Athens 11525, Greece

[2] Univ Hosp Cologne, German CLL Study Grp, Dept Internal Med 1, Cologne, Germany

[3] Univ Hosp Cologne, German CLL Study Grp, Ctr Integrated Oncol Cologne Bonn, Cologne, Germany

[4] Univ Athens, Pathol Dept, Athens, Greece

[5] Humanpathol GmbH, Pathol Dept, Erlangen, Germany

[6] Univ Athens, Laikon Gen Hosp, Dept Propedeut 1, Athens, Greece

[7] Gen Hosp Karditsa, Dept Haematol, Kardhitsa, Greece

[8] Univ Athens, Laikon Gen Hosp, Dept Haematol, Athens, Greece

[9] Univ Crete, Univ Hosp, Dept Haematol, Iraklion, Greece

来源：

ANTICANCER RESEARCH | 2019年 / 39卷 / 05期

关键词：

Small lymphocytic lymphoma; treatment; proliferation centers; PROLIFERATION CENTERS; CYCLOPHOSPHAMIDE; CLASSIFICATION; FLUDARABINE; RITUXIMAB;

D O I：

10.21873/anticanres.13382

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Only few studies have focused exclusively on patients with small lymphocytic lymphoma (SLL). Patients and Methods: In the present report, 103 SLL patients were analyzed from both, clinical trials of the German Chronic Lymphocytic Leukemia Study Group and Greek centers, and emphasis was placed on the therapeutic strategy. The impact of lymph node characteristics, such as the presence of proliferation centers (PCs) on response and survival was also assessed. Results: SLL patients included in clinical trials were treated mostly with fludarabine-based regimens while those in "reallife" were staged and treated mostly as patients with low-grade lymphomas. Our analysis showed a trend for better survival for patients with SLL without detectable PCs. Conclusion: Patients with SLL outside of clinical trials are usually treated as cases of lymphoma. In addition, this analysis supports published data regarding the adverse prognostic value of the presence of PCs in lymphoid nodes in SLL.

引用

页码：2591 / 2598

页数：8

共 50 条

[41] MONOCENTRIC REAL LIFE COHORT OF UNSELECTED CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS (CLL): ANALYSIS OF BIOLOGICAL AND CLINICAL FEATURES
Murru, R.
Loghi, M. G.
Uda, S.
Tandurella, I. M. C.
Culurgioni, F.
Pulisci, D.
Musiu, C.
Cabras, M. G.
HAEMATOLOGICA, 2017, 102 : 121 - 121
[42] Efficacy and Safety of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia: Retrospective Analysis of Real-Life Data
Tombak, Anil
Tanrikulu, Funda Pepedil
Durusoy, Salih Sertac
Dincyurek, Huseyin Derya
Kaya, Emin
Umit, Elif Gulsum
Yavasoglu, Irfan
Mehtap, Ozgur
Deveci, Burak
Ozcan, Mehmet Ali
Terzi, Hatice
Okay, Mufide
Sayinalp, Nilgun
Yilmaz, Mehmet
Okan, Vahap
Kizikli, Alperen
Ozcan, Omer
Cetin, Guven
Demircioglu, Sinan
Aydogdu, Ismet
Saydam, Guray
Davulcu, Eren Arslan
Ilhan, Gul
Ucar, Mehmet Ali
Ozet, Gulsum
Akpinar, Seval
Turgut, Burhan
Berber, Ilhami
Kurtoglu, Erdal
Sonmez, Mehmet
Batur, Derya Selim
Yildirim, Rahsan
Ozkocamaz, Vildan
Gunes, Ahmet Kursad
Sahip, Birsen
Ertop, Sehmus
Akay, Olga Meltem
Basturk, Abdulkadir
Dogu, Mehmet Hilmi
Akdeniz, Aydan
Unal, Ali
Seyhanli, Ahmet
Gurkan, Emel
Cekdemir, Demet
Ferhanoglu, Burhan
TURKISH JOURNAL OF HEMATOLOGY, 2021, 38 (04) : 273 - 285
[43] Long term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic phase treated outside clinical trials: a real-life cohort observational study
Stagno, Fabio
Breccia, Massimo
Annunziata, Mario
Trawinska, Malgorzata Monika
Iurlo, Alessandra
Sgherza, Nicola
Fava, Carmen
Gozzini, Antonella
Luciano, Luigiana
Carmosino, Ida
Bonifacio, Massimiliano
Sora, Federica
Crescenzi, Sabrina Leonetti
Crugnola, Monica
Gugliotta, Gabriele
Galimberti, Sara
Bucelli, Cristina
Colafigli, Gioia
Feo, Costanzo
Tiribelli, Mario
Mauro, Endri
Rossi, Antonella Russo
Guarini, Attilio
Abruzzese, Elisabetta
Rosti, Gianantonio
Di Raimondo, Francesco
Latagliata, Roberto
ACTA ONCOLOGICA, 2021, 60 (11) : 1527 - 1533
[44] Fludarabine (F) and Rituximab (R) (FR) as Initial Therapy for Symptomatic Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL): Population-Based Experience Matches Clinical Trials
Gerrie, Alina S.
Toze, Cynthia L.
Ramadan, Khaled M.
Li, Charles H.
Yee, Adrian
Connors, Joseph M.
BLOOD, 2009, 114 (22) : 933 - 933
[45] Bendamustine and Rituximab in combination with Lenalidomide in patients with relapsed or refractory and in patients with previously untreated chronic lymphocytic leukemia: A multicenter phase I/II safety and efficacy trial of the German Chronic Lymphocytic Leukemia Study Group (GCLLSG)
Pflug, N.
Maurer, C.
Bahlo, J.
Kluth, S.
Rhein, C.
Cramer, P.
Gross-Ophoff, C.
Langerbeins, P.
Fink, A. -M.
Eichhorst, B.
Kreuzer, K. -A.
Tausch, E.
Stilgenbauer, S.
Boettcher, S.
Doehner, H.
Kneba, M.
Hallek, M.
Wendtner, C. -M.
Bergmann, M.
Fischer, K.
Oncology Research and Treatment, 2015, 38 : 92 - 92
[46] Sequencing Therapy for Elderly Chronic Lymphocytic Leukemia Patients in the Era of Novel Therapies: An Overview of Randomized Clinical Trials
Ahmad, Malik Qistas
Sohail, Chaudhry Saad
Yasir, Muhammad
Tariq, Muhammad Junaid
Akbar, Arshia
Khalil, Muhammad Jahanzeb
Usman, Muhammad
Fraz, Muhammad Asad
Jahngir, Muhammad Umair
Khan, Ali Younas
Ijaz, Awais
Durer, Ceren
Durer, Seren
Anwer, Faiz
BLOOD, 2018, 132
[47] An Observational Study on Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax-Based Regimens Outside Clinical Trials in Italy (GIMEMA CLL1920)
Scarfo, Lydia
Albi, Elisa
Quaglia, Francesca M.
Marasca, Roberto
Sanna, Alessandro
Murru, Roberta
Laurenti, Luca
Gaidano, Gianluca
Mannina, Donato
Gentile, Massimo
Patti, Caterina
Reda, Gianluigi
Piciocchi, Alfonso
Fazi, Paola
Soddu, Stefano
Pietrasanta, Daniela
Orsucci, Lorella
Molica, Stefano
Ferrario, Andrea
Ferrari, Angela
Sportoletti, Paolo
Angeletti, Ilaria
Galimberti, Sara
Chiarenza, Annalisa
Morelli, Francesca
Mauro, Francesca
Cuneo, Antonio
Ghia, Paolo
BLOOD, 2021, 138 : 3746 - +
[48] Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experience
Herishanu, Yair
Goldschmidt, Neta
Bairey, Osnat
Ruchlemer, Rosa
Fineman, Riva
Rahimi-Levene, Naomi
Shvidel, Lev
Tadmor, Tamar
Ariel, Aviv
Braester, Andrea
Shapiro, Mika
Joffe, Erel
Polliack, Aaron
HAEMATOLOGICA, 2015, 100 (05) : 662 - 669
[49] Lymphocyte doubling time in chronic lymphocytic leukemia modern era: a real-life study in 848 unselected patients
Baumann, Tycho
Moia, Riccardo
Gaidano, Gianluca
Delgado, Julio
Condoluci, Adalgisa
Villamor, Neus
Payedimarri, Anil Babu
Costa, Dolors
Patriarca, Andrea
Jimenez-Vicente, Carlos
Rossi, Davide
Montserrat, Emili
LEUKEMIA, 2021, 35 (08) : 2325 - 2331
[50] Lymphocyte doubling time in chronic lymphocytic leukemia modern era: a real-life study in 848 unselected patients
Tycho Baumann
Riccardo Moia
Gianluca Gaidano
Julio Delgado
Adalgisa Condoluci
Neus Villamor
Anil Babu Payedimarri
Dolors Costa
Andrea Patriarca
Carlos Jiménez-Vicente
Davide Rossi
Emili Montserrat
Leukemia, 2021, 35 : 2325 - 2331

← 1 2 3 4 5 →